Incyte Corporation Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 76 Posts
1 2 3 ... 5
4 Biotech Stocks That Could Keep Beating Wall Street
Article By: Zacks Investment Research Monday, November 11, 2019 1:41 PM EDT
The size of the biotechnology market was valued at $399.4 billion in 2017 and is expected to witness a compound annual growth rate of 9.9% during the forecast period 2018-2024. Here are four stock choises.
In this article: ACAD, INCY, CHRS, BIIB Also: BMY, LLY, ADPT, CELG, TAK, ALEC, NGM
Read
5 Drug/Biotech Stocks Likely To Surpass On Earnings In Q3
Article By: Zacks Investment Research Thursday, October 24, 2019 1:40 PM EDT
The third-quarter earnings season for the pharma/biotech sector started last week, putting up an impressive performance so far in the reporting cycle.
In this article: GSK, INCY, JAZZ, VRTX, ZTS
Read
16 Stocks With The Highest Long-Term Sales Growth Rate
Article By: Benzinga Wednesday, October 23, 2019 4:20 PM EDT
Longtime investors know the stock market is forward-looking. Here are the 16 S&P 500 stocks with the biggest revenue growth over the past five years.
In this article: AGN, CNC, CRM, LEN, ABMD, INCY, AVGO, CHTR, NKTR, FB, TWTR, FANG, ANET, KHC Also: UBER, AMZN, NFLX, TSLA
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
Best And Worst Performing Nasdaq 100 Stocks Of 2018
Article By: Bespoke Investment Group Friday, May 25, 2018 1:49 PM EDT
The average stock in the Nasdaq 100 is up just over 3% year-to-date. Here is a look at the best and worst performing stocks in the Nasdaq 100 so far in 2018.
In this article: ALGN, ADBE, ADSK, AMZN, INTC, MSFT, MU, NFLX, NVDA, STX, WYNN, INCY, CELG, CMCSA, DISH, NTES, SYMC, XRAY, KHC
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Goldman Sachs: These 5 Stocks Can Break Higher
Article By: TipRanks Sunday, April 22, 2018 12:29 PM EDT
With the market in gridlock, Goldman Sachs has identified 14 stocks that seem to offer big upside potential.
In this article: NBL, NFX, ALXN, INCY, AVGO
Read
Incyte Upgraded To Buy From Neutral At UBS
Article By: The Fly Thursday, April 12, 2018 7:56 AM EDT
UBS analyst Carter Gould upgraded Incyte to Buy while lowering his price target for the shares to $76 from $106.
In this article: INCY
Read
Get Rid Of 5 Toxic Stocks Or Sell Short For Profit
Article By: Zacks Investment Research Monday, February 19, 2018 10:20 PM EDT
Accurate identification of overhyped toxic stocks and the rightly priced ones is very important for investing success. However, correctly figuring out toxic stocks and removing them at the right time to make some profits is not easy.
In this article: LYV, PTC, AROC, ATUS, INCY
Read
Biotech Year One: A Year Of Trials Tribulations And Discovery
Article By: Kieran O'Dea Monday, December 25, 2017 8:24 AM EDT
The biotech market is its own beast, derived from the aggregate opinions and knowledge of the mainstream thought. The market has a binary, linear, and simplistic approach to trial results ignoring the context in which each trial is conducted.
In this article: IBB, XBI, XPH, SPY, TEVA, AGN, JNJ, MYL, BMY, BIIB, PFE, MRK, INCY
Read
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Article By: Arpita Dutt Monday, December 11, 2017 7:45 PM EDT
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.
In this article: JUNO, BLUE, INCY Also: SNY, AMGN, JNJ, GILD
Read
5 Toxic Stocks To Discard Or Sell Short For Profit
Article By: Zacks Investment Research Friday, September 22, 2017 11:17 AM EDT
Investors who can accurately distinguish between overpriced and rightly priced stocks emerge as winners at the end.
In this article: APA, TWI, CARB, INCY, PTC
Read
Biotechs Weaken On Profit Taking
Article By: Rod Raynovich Tuesday, July 25, 2017 8:36 PM EDT
The nine month biotech rally hit a bit of a sell-off today after leading all sectors of the market through the first half of 2017. The healthcare sector was also the laggard today as money shifted to basic materials, energy and cyclicals.
In this article: CAT, ALNY, IBB, INCY, AMGN, BIIB, VRTX, XBI, XLV
Read
Stocks Watchlist: INCY, CAVM, ACM
Article By: Ryan Mallory Monday, July 24, 2017 1:10 AM EDT
Today's stock picks include Incyte, Cavium Networks and Aecom Technology.
In this article: ACM, CAVM, INCY
Read
Stock Exchange: Should You Embrace Evidence-Based Trading?
Article By: Jeff Miller Friday, June 30, 2017 5:33 AM EDT
This week’s choices cover a wide range – different sectors, market caps and risk-reward.
In this article: HTZ, INCY, OII, NTES
Read
Good Day Today: XBI Breaks Through To YTD Highs
Article By: Rod Raynovich Monday, June 19, 2017 9:31 PM EDT
Tech stocks rebounded today and biotech stocks soared and maintained the market lead in 2017 performance.
In this article: BMY, ALNY, BMRN, INCY, QQQ, AMGN, CLVS, GILD, XBI, XLV, ICPT, BLUE, RDUS, IBB
Read
1 to 16 of 76 Posts
1 2 3 ... 5